Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Boehringer and f-star form antibody collaboration

Executive Summary

Boehringer Ingelheim GMBH and f-star Biotechnology Research & Development Co. (enhances antibodies and antibody fragments) have agreed to jointly discover small-sized antibodies called Fcabs against seven targets--covering possibly many indications--identified by BI. The companies will use f-star's Modular Antibody Technology.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies